TABLE 3

Measurements of ¹⁸F-Fluciclovine and ¹⁸F-FDG Avidity in Primary Breast Malignancies, Axillary Nodes, and Extraaxillary Nodes of 14 Patients Who Underwent Both ¹⁸F-Fluciclovine PET/CT and ¹⁸F-FDG PET/CT

					By histology
		All patients (n = 14)			IDC (n = 10)			ILC (n = 4)
Lesion site	Measurements of avidity	n	Median	Minimum to maximum	n	Median	Minimum to maximum	n	Median	Minimum to maximum
¹⁸F-fluciclovine
Breast malignancy	SUV_max	14	6.8	3.6–10.9	10	6.8	3.6−9.9	4	6.1	4.5−10.9
	SUV_mean		3.5	2.1–5.8		3.5	2.1−5.2		3.6	2.5−5.8
	MTV		18.2	3.2–102.0		14.2	3.2−74.6		54.7	34.7−102.0
	TLA		59.8	16.6–370.6		43.0	16.6–276.0		227	97.2–370.6
Axillary nodes	SUV_max	13	5.8	1.3–14.6	10	5.4	1.3–12.6	3	8.2	5.8–14.6
	SUV_mean		3.5	1.0–7.9		3.2	1.0–7.9		4.9	3.5–6.2
	MTV		5.2	1.0–22.1		5.2	1.0–13.4		4.1	2.2–22.1
	TLA		16.7	1.0–137.0		17.0	1.0–52.3		14.4	10.8–137.0
Extraaxillary nodes	SUV_max	2	3.4	2.6–4.2	2	3.4	2.6–4.2	0
	SUV_mean		2.6	1.8–3.3		2.6	1.8–3.3
	MTV		1.6	1.4–1.8		1.6	1.4–1.8
	TLA		3.9	3.2–4.6		3.9	3.2–4.6
¹⁸F-FDG
Breast malignancy	SUV_max	14	6.2	1.8–43.5	10	10.0	3.3–43.5	4	3.7	1.8–6.0
	SUV_mean		3.7	1.6–15.1		4.5	2.4–15.1		2.4	1.6–3.6
	MTV		13.7	1.1–143.0		11.5	2.6–63.3		43.5	1.1–143.0
	TLG		62.4	1.9–673.5		49.7	6.2–673.5		148	1.9–228.8
Axillary nodes	SUV_max	13	6.3	2.8–13.3	10	6.4	3.2–13.3	3	6.3	2.8–9.0
	SUV_mean		3.9	1.8–6.9		4.2	1.8–6.9		3.9	2.2–5.6
	MTV		3.7	1.3–11.8		3.7	1.3–11.8		2.2	1.5–10.7
	TLG		13.0	3.3–71.8		17.2	3.7–71.8		8.6	3.3–59.9
Extraaxillary nodes	SUV_max	2	4.9	2.8–6.9	2	4.9	2.8–6.9	0
	SUV_mean		2.8	2.1–3.5		2.8	2.1–3.5
	MTV		2.0	1.5–2.4		2.0	1.5–2.4
	TLG		5.1	5.0–5.3		5.1	5.0–5.3